MedTrace Logo

Fibrosis in Chronic and Delayed Myocardial Infarction

NCT05756608 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2026-01-09

No results posted yet for this study

Summary

In this study the investigators aim to examine the role that fibrosis plays in heart conditions such as aortic stenosis , chemotherapy-induced cardiotoxicity and carcinoid syndrome . Fibrosis is a common final result following any injury to the heart muscle and the investigators aim to identify this process early and in its active state. This will be examined by using a radiotracer 68Ga-FAPI or 18F-AlF-FAPI and PET-MRI or PET-CT.

Conditions

  • Aortic Stenosis
  • Chemotherapy Induced Systolic Dysfunction
  • Carcinoid Syndrome

Interventions

DIAGNOSTIC_TEST

68Ga-FAPI and 18F-AlF-FAPI PET-MR

Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer

Sponsors & Collaborators

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • Marc Dweck, MBBS PhD · University of Edinburgh

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-10
Primary Completion
2028-08-31
Completion
2028-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05756608 on ClinicalTrials.gov